间歇性多拉韦林/拉米夫定/富马酸替诺福韦二酯（DOR/3TC/TDF）在病毒抑制的HIV感染者中保持高水平的病毒抑制。

IF 2.9 4区医学 Q2 INFECTIOUS DISEASES

Infectious diseases now Pub Date : 2023-10-01 DOI:10.1016/j.idnow.2023.104736

Romain Palich , Sanaa Saliba , Stéphanie Landowski , Basma Abdi , Marc-Antoine Valantin , Rezak Mahrez , Christine Katlama , Pierre de Truchis

{"title":"间歇性多拉韦林/拉米夫定/富马酸替诺福韦二酯（DOR/3TC/TDF）在病毒抑制的HIV感染者中保持高水平的病毒抑制。","authors":"Romain Palich , Sanaa Saliba , Stéphanie Landowski , Basma Abdi , Marc-Antoine Valantin , Rezak Mahrez , Christine Katlama , Pierre de Truchis","doi":"10.1016/j.idnow.2023.104736","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>We aimed to determine whether doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) given 5 or 4 days a week was able to maintain viral suppression in people living with HIV (PLHIV).</p></div><div><h3>Methods</h3><p>In this observational, retrospective study, we included all PLHIVs who had received intermittent DOR/3TC/TDF between 10/01/2019 and 01/31/2021, in two French hospitals.</p></div><div><h3>Results</h3><p>Forty-three PLHIVs were included, median (IQR) age: 52 years (48–58), ART duration: 15 years (8–23), duration of virological suppression: 6 years (2–10). Median follow-up was 78 weeks (IQR 62–97). One virological failure (VF) occurred at W38 (HIV-RNA = 61 and 76 copies/mL), in a patient with no viral resistance at baseline or at time of VF, and during the study period five individuals discontinued DOR/3TC/TDF due to adverse events. There were no significant changes during follow-up in the CD4 count, CD4/CD8 ratio, body weight or residual viremia rate.</p></div><div><h3>Conclusion</h3><p>These findings suggest the potential for intermittent DOR/3TC/TDF to maintain virological control.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains a high level of viral suppression in virologically suppressed people living with HIV\",\"authors\":\"Romain Palich , Sanaa Saliba , Stéphanie Landowski , Basma Abdi , Marc-Antoine Valantin , Rezak Mahrez , Christine Katlama , Pierre de Truchis\",\"doi\":\"10.1016/j.idnow.2023.104736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>We aimed to determine whether doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) given 5 or 4 days a week was able to maintain viral suppression in people living with HIV (PLHIV).</p></div><div><h3>Methods</h3><p>In this observational, retrospective study, we included all PLHIVs who had received intermittent DOR/3TC/TDF between 10/01/2019 and 01/31/2021, in two French hospitals.</p></div><div><h3>Results</h3><p>Forty-three PLHIVs were included, median (IQR) age: 52 years (48–58), ART duration: 15 years (8–23), duration of virological suppression: 6 years (2–10). Median follow-up was 78 weeks (IQR 62–97). One virological failure (VF) occurred at W38 (HIV-RNA = 61 and 76 copies/mL), in a patient with no viral resistance at baseline or at time of VF, and during the study period five individuals discontinued DOR/3TC/TDF due to adverse events. There were no significant changes during follow-up in the CD4 count, CD4/CD8 ratio, body weight or residual viremia rate.</p></div><div><h3>Conclusion</h3><p>These findings suggest the potential for intermittent DOR/3TC/TDF to maintain virological control.</p></div>\",\"PeriodicalId\":13539,\"journal\":{\"name\":\"Infectious diseases now\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases now\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666991923000982\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991923000982","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

引言：我们的目的是确定每周5或4天给予多拉韦林/拉米夫定/富马酸替诺福韦二酯（DOR/3TC/TDF）是否能够在HIV感染者中保持病毒抑制。方法：在这项观察性回顾性研究中，我们纳入了2019年1月10日至2021年1月31日期间在两家法国医院接受间歇性DOR/3TC/TDF治疗的所有PLHIV感染者。结果：纳入43例PLHIVs，中位（IQR）年龄：52岁（48-58），ART持续时间：15年（8-23），病毒学抑制持续时间：6年（2-10）。中位随访时间为78周（IQR 62-97）。在W38（HIV-RNA=61和76拷贝/mL）发生一例病毒学失败（VF），患者在基线或VF时没有病毒耐药性，在研究期间，有5名患者因不良事件停止DOR/3TC/TDF。在随访期间，CD4计数、CD4/CD8比率、体重或残余病毒血症率没有显著变化。结论：这些发现表明间歇性DOR/3TC/TDF有可能维持病毒学控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intermittent doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains a high level of viral suppression in virologically suppressed people living with HIV

Introduction

We aimed to determine whether doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) given 5 or 4 days a week was able to maintain viral suppression in people living with HIV (PLHIV).

Methods

In this observational, retrospective study, we included all PLHIVs who had received intermittent DOR/3TC/TDF between 10/01/2019 and 01/31/2021, in two French hospitals.

Results

Forty-three PLHIVs were included, median (IQR) age: 52 years (48–58), ART duration: 15 years (8–23), duration of virological suppression: 6 years (2–10). Median follow-up was 78 weeks (IQR 62–97). One virological failure (VF) occurred at W38 (HIV-RNA = 61 and 76 copies/mL), in a patient with no viral resistance at baseline or at time of VF, and during the study period five individuals discontinued DOR/3TC/TDF due to adverse events. There were no significant changes during follow-up in the CD4 count, CD4/CD8 ratio, body weight or residual viremia rate.